The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study
Mary R. Lee(National Institute on Drug Abuse), Lorenzo Leggio(National Institute on Drug Abuse), Lisa A. Farinelli(National Institute on Drug Abuse), Fatemeh Akhlaghi(University of Rhode Island), Mwlod Ghareeb(University of Rhode Island), Melanie L. Schwandt(National Institute on Alcohol Abuse and Alcoholism), Jenica D. Tapocik(National Institutes of Health), Mehdi Farokhnia(National Institutes of Health), Alexandra A. Dias(National Institute on Drug Abuse), Sofia Bouhlal(National Institute on Drug Abuse), Markus Heilig(Linköping University), April Le(National Institute on Drug Abuse), Enoch Cobbina(University of Rhode Island)
Cited by 127
Related Papers
Addiction as a brain disease revised: why it still matters, and the need for consilience
|Neuropsychopharmacology|2021|272
Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay
|Molecular Psychiatry|2017|241
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
|JCI Insight|2023|200
Rescue of Infralimbic mGluR<sub>2</sub>Deficit Restores Control Over Drug-Seeking Behavior in Alcohol Dependence
|Journal of Neuroscience|2013|173
Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review
|Pharmacological Reviews|2022|155